

Connecting via Winsock to STN

Welcome to STN International! Enter x:X

LOGINID:SSPTAJHM1624

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

***** Welcome to STN International *****

NEWS 1 Web Page for STN Seminar Schedule - N. America
NEWS 2 JAN 02 STN pricing information for 2008 now available
NEWS 3 JAN 16 CAS patent coverage enhanced to include exemplified
prophetic substances
NEWS 4 JAN 28 USPATFULL, USPAT2, and USPATOLD enhanced with new
custom IPC display formats
NEWS 5 JAN 28 MARPAT searching enhanced
NEWS 6 JAN 28 USGENE now provides USPTO sequence data within 3 days
of publication
NEWS 7 JAN 28 TOXCENTER enhanced with reloaded MEDLINE segment
NEWS 8 JAN 28 MEDLINE and LMEEDLINE reloaded with enhancements
NEWS 9 FEB 08 STN Express, Version 8.3, now available
NEWS 10 FEB 20 PCI now available as a replacement to DPCI
NEWS 11 FEB 25 IFIREF reloaded with enhancements
NEWS 12 FEB 25 IMSPRODUCT reloaded with enhancements
NEWS 13 FEB 29 WPINDEX/WPIDS/WPIX enhanced with ECLA and current
U.S. National Patent Classification
NEWS 14 MAR 31 IFICDB, IFIPAT, and IFIUDB enhanced with new custom
IPC display formats
NEWS 15 MAR 31 CAS REGISTRY enhanced with additional experimental
spectra
NEWS 16 MAR 31 CA/CAPLUS and CASREACT patent number format for U.S.
applications updated
NEWS 17 MAR 31 LPCI now available as a replacement to LDPCI
NEWS 18 MAR 31 EMBASE, EMBAL, and LEMBASE reloaded with enhancements
NEWS 19 APR 04 STN AnaVist, Version 1, to be discontinued

NEWS EXPRESS FEBRUARY 08 CURRENT WINDOWS VERSION IS V8.3,
AND CURRENT DISCOVER FILE IS DATED 20 FEBRUARY 2008

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS LOGIN Welcome Banner and News Items
NEWS IPC8 For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that
specific topic.

All use of STN is subject to the provisions of the STN Customer
agreement. Please note that this agreement limits use to scientific
research. Use for software development or design or implementation
of commercial gateways or other similar uses is prohibited and may
result in loss of user privileges and other penalties.

***** STN Columbus *****

FILE 'HOME' ENTERED AT 13:28:16 ON 09 APR 2008

=> file registry
COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
0.21	0.21

FULL ESTIMATED COST

FILE 'REGISTRY' ENTERED AT 13:28:37 ON 09 APR 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 8 APR 2008 HIGHEST RN 1012980-81-2
DICTIONARY FILE UPDATES: 8 APR 2008 HIGHEST RN 1012980-81-2

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 9, 2008.

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=>

Uploading C:\Program Files\Stnexp\Queries\10 series\10545190\10545190a.str



```

chain nodes :
10 11 12
ring nodes :
1 2 3 4 5 6 7 8 9
chain bonds :
1-10 10-11 11-12
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-9 7-8 8-9
exact/norm bonds :
1-2 1-6 1-10 2-3 3-4 4-5 5-6 5-7 6-9 8-9 10-11 11-12
exact bonds :
7-8
isolated ring systems :
containing 1 :
```

G1:O,S,NH

Match level :


1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:CLASS
11:CLASS 12:Atom

L1 STRUCTURE UPLOADED

=> d l1

L1 HAS NO ANSWERS

L1 STR



G1 O,S,NH

Structure attributes must be viewed using STN Express query preparation.

=> s l1

SAMPLE SEARCH INITIATED 13:29:01 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 2678 TO ITERATE

74.7% PROCESSED 2000 ITERATIONS

10 ANSWERS

INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**

BATCH **COMPLETE**

PROJECTED ITERATIONS: 50456 TO 56664

PROJECTED ANSWERS: 48 TO 486


L2 10 SEA SSS SAM L1

=> d scan

L2 10 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN

IN Urea, N-(5-chloro-2-phenoxyphenyl)-N'-[3-[8-[(4-pyridinylmethyl)amino]imidazo[1,2-a]pyrazin-6-yl]phenyl]-


MF C31 H24 Cl N7 O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):2

L2 10 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
 IN Imidazo[1,2-a]pyrazin-8-amine, 6-phenyl-N-(3-pyridinylmethyl)-
 MF C18 H15 N5



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 10 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
 IN Imidazo[1,2-a]pyrazine-6-carboxamide, 8-[[[(2-ethyl-6-methylphenyl)methyl]amino]-N-(2-methoxyethyl)-2,3-dimethyl-
 MF C22 H29 N5 O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):0

=> s l1 full

FULL SEARCH INITIATED 13:29:20 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 53781 TO ITERATE

100.0% PROCESSED 53781 ITERATIONS

232 ANSWERS

SEARCH TIME: 00.00.03


L3 232 SEA SSS FUL L1

=> d scan

L3 232 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN

IN Imidazo[1,2-a]pyrazin-8-amine, 6-[3-(dimethylamino)phenyl]-N-(3-pyridinylmethyl)-

MF C20 H20 N6



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):0

=> file caplus		
COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	178.82	179.03

FILE 'CAPLUS' ENTERED AT 13:29:33 ON 09 APR 2008
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 9 Apr 2008 VOL 148 ISS 15
 FILE LAST UPDATED: 8 Apr 2008 (20080408/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

```
=> s l3
L4          47 L3

=> s l3 and (pd<=20030218 or ad<=20030218 or prd<=20030218)
          47 L3
          23674917 PD<=20030218
              (PD<=20030218)
          4510797 AD<=20030218
              (AD<=20030218)
          3986255 PRD<=20030218
              (PRD<=20030218)
L5          29 L3 AND (PD<=20030218 OR AD<=20030218 OR PRD<=20030218)

=> d l5 1-29 ibib hitstr
```

```
L5  ANSWER 1 OF 29  CAPLUS  COPYRIGHT 2008 ACS ON STN
ACCESSION NUMBER:    2006:463553  CAPLUS
DOCUMENT NUMBER:     144:488677
TITLE:               Preparation of novel imidazopyrazines as cyclin
                      dependent kinase inhibitors
INVENTOR(S):         Guzi, Timothy J.; Paruch, Kamil; Dwyer, Michael P.;
                      Zhao, Lianyun; Curran, Patrick J.; Belanger, David B.;
                      Hamann, Blake; Reddy, Panduranga A.; Siddiqui, M.
                      Arshad
PATENT ASSIGNEE(S):  Schering Corporation, USA
SOURCE:              U.S. Pat. Appl. Publ., 161 pp., Cont.-in-part of U.S.
                      Ser. No. 47,524.
                      CODEN: USXXCO
DOCUMENT TYPE:       Patent
LANGUAGE:            English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:
```

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20060106023	A1	20060518	US 2005-272392	20051110 <--
US 20040063715	A1	20040401	US 2003-665005	20030919 <--
US 6919341	B2	20050719		
US 20050130980	A1	20050616	US 2005-47524	20050131 <--
WO 2007058873	A2	20070524	WO 2006-US43592	20061108
WO 2007058873	A3	20070719		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA

AU 2007200401 A1 20070222 AU 2007-200401 20070131

PRIORITY APPLN. INFO.:
 US 2002-412997P P 20020923 <--
 US 2003-665005 A3 20030919
 US 2005-47524 A2 20050131
 AU 2003-272476 A3 20030919
 US 2005-272392 A 20051110

OTHER SOURCE(S): MARPAT 144:488677


IT 676359-71-0P 676359-82-3P 676359-86-7P
 676359-88-9P 676359-92-5P 676359-94-7P
 676359-98-1P 676360-00-2P 676360-02-4P
 676360-05-7P 676360-09-1P 676360-11-5P
 676360-29-5P 676360-37-5P 676360-41-1P
 676360-43-3P

RL: CPN (Combinatorial preparation); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); CMBI (Combinatorial study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of novel imidazopyrazines as cyclin dependent kinase inhibitors useful in treatment and prevention of various diseases)

RN 676359-71-0 CAPLUS


CN Imidazo[1,2-a]pyrazin-8-amine, 3-bromo-6-(2-chlorophenyl)-N-(cyclopropylmethyl)- (CA INDEX NAME)



RN 676359-82-3 CAPLUS


CN Imidazo[1,2-a]pyrazin-8-amine, 3-bromo-6-(2-chlorophenyl)-N-[(tetrahydro-2-

furanyl)methyl]- (CA INDEX NAME)




RN 676359-86-7 CAPLUS

CN Imidazo[1,2-a]pyrazin-8-amine, 3-bromo-6-(2-chlorophenyl)-N-(2-thienylmethyl)- (CA INDEX NAME)




RN 676359-88-9 CAPLUS

CN Imidazo[1,2-a]pyrazin-8-amine, 3-bromo-6-(2-chlorophenyl)-N-(cyclohexylmethyl)- (CA INDEX NAME)




RN 676359-92-5 CAPLUS

CN Imidazo[1,2-a]pyrazin-8-amine, 3-bromo-6-(2-chlorophenyl)-N-(1-phenylethyl)- (CA INDEX NAME)




RN 676359-94-7 CAPLUS

CN Imidazo[1,2-a]pyrazin-8-amine, 3-bromo-6-(2-chlorophenyl)-N-(2-phenylethyl)- (CA INDEX NAME)




RN 676359-98-1 CAPLUS

CN Imidazo[1,2-a]pyrazin-8-amine, 3-bromo-6-(2-chlorophenyl)-N-(2-phenylpropyl)- (CA INDEX NAME)




RN 676360-00-2 CAPLUS

CN Imidazo[1,2-a]pyrazin-8-amine, 3-bromo-6-(2-chlorophenyl)-N-[(3-methoxyphenyl)methyl]- (CA INDEX NAME)




RN 676360-02-4 CAPLUS

CN Imidazo[1,2-a]pyrazin-8-amine, 3-bromo-6-(2-chlorophenyl)-N-[(3-chlorophenyl)methyl]- (CA INDEX NAME)




RN 676360-05-7 CAPLUS

CN Imidazo[1,2-a]pyrazin-8-amine, 3-bromo-6-(2-chlorophenyl)-N-[1-(4-chlorophenyl)ethyl]- (CA INDEX NAME)




RN 676360-09-1 CAPLUS

CN Imidazo[1,2-a]pyrazin-8-amine, 3-bromo-6-(2-chlorophenyl)-N-[[4-(trifluoromethyl)phenyl]methyl]- (CA INDEX NAME)




RN 676360-11-5 CAPLUS

CN Imidazo[1,2-a]pyrazin-8-amine, 3-bromo-6-(2-chlorophenyl)-N-(2,2-diphenylethyl)- (CA INDEX NAME)



RN 676360-29-5 CAPLUS


CN Imidazo[1,2-a]pyrazin-8-amine, 3-bromo-6-(2-chlorophenyl)-N-(3-pyridinylmethyl)- (CA INDEX NAME)



RN 676360-37-5 CAPLUS


CN Imidazo[1,2-a]pyrazin-8-amine, 3-bromo-6-(2-chlorophenyl)-N-[(1-ethyl-2-

pyrrolidinyl)methyl]- (CA INDEX NAME)




RN 676360-41-1 CAPLUS

CN Imidazo[1,2-a]pyrazin-8-amine, 3-bromo-6-(2-chlorophenyl)-N-[2-(1-methyl-2-pyrrolidinyl)ethyl]- (CA INDEX NAME)



RN 676360-43-3 CAPLUS

CN Imidazo[1,2-a]pyrazin-8-amine, 3-bromo-6-(2-chlorophenyl)-N-[2-(4-morpholinyl)ethyl]- (CA INDEX NAME)




IT 676359-53-8P 676360-96-6P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(drug candidate; preparation of novel imidazopyrazines as cyclin dependent kinase inhibitors useful in treatment and prevention of various diseases)


RN 676359-53-8 CAPLUS

CN Ethanone, 1-[6-phenyl-8-[(3-pyridinylmethyl)amino]imidazo[1,2-a]pyrazin-3-yl]- (CA INDEX NAME)



RN 676360-96-6 CAPLUS

CN Imidazo[1,2-a]pyrazin-8-amine, 3-iodo-6-phenyl-N-(3-pyridinylmethyl)- (CA INDEX NAME)




IT 676359-47-0P 676359-49-2P 676359-51-6P
 676359-55-0P 676359-56-1P 676359-58-3P
 676359-60-7P 676359-65-2P 676359-67-4P
 676359-70-9P 676360-59-1P 676360-61-5P
 676360-63-7P 676360-65-9P 676360-67-1P
 676360-69-3P 676360-76-2P 676360-78-4P
 676360-80-8P 676360-82-0P 676360-84-2P
 676360-86-4P 676360-91-1P 676361-00-5P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of novel imidazopyrazines as cyclin dependent kinase inhibitors useful in treatment and prevention of various diseases)


RN 676359-47-0 CAPLUS

CN Imidazo[1,2-a]pyrazin-8-amine, 3,6-diphenyl-N-(3-pyridinylmethyl)- (CA INDEX NAME)




RN 676359-49-2 CAPLUS


CN Imidazo[1,2-a]pyrazin-8-amine, 6-phenyl-N-(3-pyridinylmethyl)-3-(3-thienyl)- (CA INDEX NAME)




RN 676359-51-6 CAPLUS
 CN Imidazo[1,2-a]pyrazin-8-amine, 3-ethenyl-6-phenyl-N-(3-pyridinylmethyl)-
 (CA INDEX NAME)




RN 676359-55-0 CAPLUS
 CN Imidazo[1,2-a]pyrazine-3-methanol, α,α -dimethyl-6-phenyl-8-[(3-pyridinylmethyl)amino]-
 (CA INDEX NAME)




RN 676359-56-1 CAPLUS
 CN Imidazo[1,2-a]pyrazin-8-amine, 3-methyl-N-(3-pyridinylmethyl)-
 (CA INDEX NAME)




RN 676359-58-3 CAPLUS
 CN Imidazo[1,2-a]pyrazin-8-amine, 3-methyl-N-(phenylmethyl)- (CA INDEX NAME)



RN 676359-60-7 CAPLUS
 CN Imidazo[1,2-a]pyrazin-8-amine, 3-methyl-N-[2-(4-pyridinyl)ethyl]- (CA INDEX NAME)




RN 676359-65-2 CAPLUS
 CN Imidazo[1,2-a]pyrazin-8-amine, 3-methyl-N-(4-pyridinylmethyl)- (CA INDEX NAME)




RN 676359-67-4 CAPLUS

CN Imidazo[1,2-a]pyrazin-8-amine, N-(diphenylmethyl)-3-methyl- (CA INDEX NAME)




RN 676359-70-9 CAPLUS

CN Imidazo[1,2-a]pyrazin-8-amine, 3-bromo-6-phenyl-N-(5-pyrimidinylmethyl)- (CA INDEX NAME)




RN 676360-59-1 CAPLUS

CN 2-Piperidineethanol, 1-[3-bromo-8-[(3-pyridinylmethyl)amino]imidazo[1,2-a]pyrazin-6-yl]- (CA INDEX NAME)




RN 676360-61-5 CAPLUS

CN Cyclohexanol, 2-[[3-bromo-8-[(3-pyridinylmethyl)amino]imidazo[1,2-a]pyrazin-6-yl]amino]- (CA INDEX NAME)




RN 676360-63-7 CAPLUS

CN Cyclohexanemethanol, 2-[[3-bromo-8-[(3-pyridinylmethyl)amino]imidazo[1,2-a]pyrazin-6-yl]amino]- (CA INDEX NAME)




RN 676360-65-9 CAPLUS

CN 1-Butanol, 2-[[3-bromo-8-[(3-pyridinylmethyl)amino]imidazo[1,2-a]pyrazin-6-yl]amino]-3-methyl- (CA INDEX NAME)




RN 676360-67-1 CAPLUS

CN Imidazo[1,2-a]pyrazin-8-amine, 3-bromo-6-phenyl-N-(4-pyridinylmethyl)-
(CA INDEX NAME)




RN 676360-69-3 CAPLUS

CN Imidazo[1,2-a]pyrazin-8-amine, 3-bromo-6-phenyl-N-(3-pyridinylmethyl)-
(CA INDEX NAME)




RN 676360-76-2 CAPLUS

CN Imidazo[1,2-a]pyrazin-8-amine, 3-bromo-6-phenyl-N-[2-(4-pyridinyl)ethyl]-
(CA INDEX NAME)




RN 676360-78-4 CAPLUS

CN Imidazo[1,2-a]pyrazin-8-amine, 3-bromo-6-phenyl-N-[2-(3-pyridinyl)ethyl]-
(CA INDEX NAME)




RN 676360-80-8 CAPLUS

CN Imidazo[1,2-a]pyrazin-8-amine, 3-iodo-6-phenyl-N-(4-pyridinylmethyl)-
(CA INDEX NAME)




RN 676360-82-0 CAPLUS

CN Imidazo[1,2-a]pyrazin-8-amine, 3-bromo-6-(2-chlorophenyl)-N-(4-pyridinylmethyl)-
(CA INDEX NAME)




RN 676360-84-2 CAPLUS

CN Imidazo[1,2-a]pyrazin-8-amine, 6-(2-chlorophenyl)-3-iodo-N-(4-pyridinylmethyl)- (CA INDEX NAME)




RN 676360-86-4 CAPLUS

CN Imidazo[1,2-a]pyrazin-8-amine, 6-(2-chlorophenyl)-3-iodo-N-(3-pyridinylmethyl)- (CA INDEX NAME)




RN 676360-91-1 CAPLUS

CN Imidazo[1,2-a]pyrazin-8-amine, 3-chloro-6-(2-chlorophenyl)-N-(3-pyridinylmethyl)- (CA INDEX NAME)



RN 676361-00-5 CAPLUS

CN Imidazo[1,2-a]pyrazin-8-amine, 3-bromo-6-phenyl-N-[(6-(trifluoromethyl)-3-pyridinyl)methyl]- (CA INDEX NAME)



IT 887474-59-1P 887474-60-4P 887474-61-5P


887474-68-2P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of novel imidazopyrazines as cyclin dependent kinase inhibitors useful in treatment and prevention of various diseases)


RN 887474-59-1 CAPLUS

CN Imidazo[1,2-a]pyrazin-8-amine, 3-(1-methyl-1H-pyrazol-4-yl)-N-(3-pyrrolidinylmethyl)- (CA INDEX NAME)




RN 887474-60-4 CAPLUS

CN Imidazo[1,2-a]pyrazin-8-amine, 3-(1-methyl-1H-pyrazol-4-yl)-N-(4-piperidinylmethyl)- (CA INDEX NAME)




RN 887474-61-5 CAPLUS

CN Imidazo[1,2-a]pyrazin-8-amine, 3-(1-methyl-1H-pyrazol-4-yl)-N-[2-(4-morpholinyl)ethyl]- (CA INDEX NAME)



RN 887474-68-2 CAPLUS
 CN 3-Pyridinecarboxamide, N-[3-(1-methyl-1H-pyrazol-4-yl)imidazo[1,2-a]pyrazin-8-yl]- (CA INDEX NAME)




L5 ANSWER 2 OF 29 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2004:718541 CAPLUS
 DOCUMENT NUMBER: 141:243569
 TITLE: Preparation of 6-substituted imidazopyrazines with gastric antisecretory activity for treatment of gastrointestinal disorders
 INVENTOR(S): Chiesa, M. Vittoria; Palmer, Andreas; Brehm, Christof; Grundler, Gerhard; Senn-Bilfinger, Joerg; Simon, Wolfgang-Alexander; Postius, Stefan; Kromer, Wolfgang; Zimmermann, Peter Jan; Buhr, Wilm
 PATENT ASSIGNEE(S): Altana Pharma A.-G., Germany
 SOURCE: PCT Int. Appl., 30 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004074289	A1	20040902	WO 2004-EP50135	20040216 <--
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI			
RW:	BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
AU 2004213177	A1	20040902	AU 2004-213177	20040216 <--
CA 2516021	A1	20040902	CA 2004-2516021	20040216 <--
EP 1599481	A1	20051130	EP 2004-711383	20040216 <--
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			
BR 2004007390	A	20060207	BR 2004-7390	20040216 <--
CN 1747956	A	20060315	CN 2004-80003928	20040216 <--
JP 2006517951	T	20060803	JP 2006-502029	20040216 <--
ZA 2005005670	A	20060426	ZA 2005-5670	20050714 <--
IN 2005MN00979	A	20060120	IN 2005-MN979	20050908 <--
NO 2005004199	A	20051117	NO 2005-4199	20050909 <--

US 20060148796	A1	20060706	US 2005-545190	20051109	<--
PRIORITY APPLN. INFO.:			EP 2003-3652	A	20030218 <--
			WO 2004-EP50135	A	20040216

OTHER SOURCE(S): MARPAT 141:243569


IT	750571-41-6P, 6-Bromo-8-[(2-ethyl-6-methylbenzyl)amino]-2,3-dimethylimidazo[1,2-a]pyrazine 750571-42-7P, 6-Bromo-8-[(2-ethyl-6-methylbenzyl)amino]-2,3-dimethylimidazo[1,2-a]pyrazine oxalate 750571-43-8P, Ethyl 8-[(2-ethyl-6-methylbenzyl)amino]-2,3-dimethylimidazo[1,2-a]pyrazine-6-carboxylate 750571-45-0P, 8-[(2-Ethyl-6-methylbenzyl)amino]-2,3-dimethylimidazo[1,2-a]pyrazine-6-carboxylic acid 750571-51-8P, 8-[(2-Ethyl-6-methylbenzyl)amino]-6-(hydroxymethyl)-2,3-dimethylimidazo[1,2-a]pyrazine
RL:	PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
	(drug candidate; preparation of imidazopyrazines with gastric antisecretory activity for treatment of gastrointestinal disorders)
RN	750571-41-6 CAPLUS
CN	Imidazo[1,2-a]pyrazin-8-amine, 6-bromo-N-[(2-ethyl-6-methylphenyl)methyl]-2,3-dimethyl- (CA INDEX NAME)



RN 750571-42-7 CAPLUS
CN Imidazo[1,2-a]pyrazin-8-amine, 6-bromo-N-[(2-ethyl-6-methylphenyl)methyl]-2,3-dimethyl-, ethanedioate (1:1) (CA INDEX NAME)

CM 1

CRN 750571-41-6
CMF C18 H21 Br N4



CM 2


CRN 144-62-7

CMF C2 H2 O4




RN 750571-43-8 CAPLUS

CN Imidazo[1,2-a]pyrazine-6-carboxylic acid, 8-[[[(2-ethyl-6-methylphenyl)methyl]amino]-2,3-dimethyl-, ethyl ester (CA INDEX NAME)




RN 750571-45-0 CAPLUS

CN Imidazo[1,2-a]pyrazine-6-carboxylic acid, 8-[[[(2-ethyl-6-methylphenyl)methyl]amino]-2,3-dimethyl- (CA INDEX NAME)




RN 750571-51-8 CAPLUS


CN Imidazo[1,2-a]pyrazine-6-methanol, 8-[[[(2-ethyl-6-methylphenyl)methyl]amino]-2,3-dimethyl- (CA INDEX NAME)



IT 750571-44-9P, 6-[(Dimethylamino)carbonyl]-8-[(2-ethyl-6-methylbenzyl)amino]-2,3-dimethylimidazo[1,2-a]pyrazine 750571-46-1P, 8-[(2-Ethyl-6-methylbenzyl)amino]-6-(pyrrolidinocarbonyl)-2,3-dimethylimidazo[1,2-a]pyrazine 750571-47-2P, 8-[(2-Ethyl-6-methylbenzyl)amino]-2,3-dimethylimidazo[1,2-a]pyrazine-6-carboxamide 750571-48-3P, 8-[(2-Ethyl-6-methylbenzyl)amino]-6-[(methylamino)carbonyl]-2,3-dimethylimidazo[1,2-a]pyrazine 750571-49-4P, 8-[(2-Ethyl-6-methylbenzyl)amino]-6-[[2-methoxyethyl)amino]carbonyl]-2,3-dimethylimidazo[1,2-a]pyrazine 750571-50-7P, 8-[(2-Ethyl-6-methylbenzyl)amino]-6-[[2-hydroxyethyl)amino]carbonyl]-2,3-dimethylimidazo[1,2-a]pyrazine 750571-52-9P, 8-[(2-Ethyl-6-methylbenzyl)amino]-6-(methoxymethyl)-2,3-dimethylimidazo[1,2-a]pyrazine hydrochloride 750571-53-0P, 8-[(2-Ethyl-6-methylbenzyl)amino]-6-(methoxymethyl)-2,3-dimethylimidazo[1,2-a]pyrazine
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (drug candidate; preparation of imidazopyrazines with gastric antisecretory activity for treatment of gastrointestinal disorders)
 RN 750571-44-9 CAPLUS
 CN Imidazo[1,2-a]pyrazine-6-carboxamide, 8-[[2-ethyl-6-methylphenyl)methyl]amino]-N,N,2,3-tetramethyl- (CA INDEX NAME)




RN 750571-46-1 CAPLUS
 CN Methanone, [8-[[2-ethyl-6-methylphenyl)methyl]amino]-2,3-dimethylimidazo[1,2-a]pyrazin-6-yl]-1-pyrrolidinyl- (CA INDEX NAME)




RN 750571-47-2 CAPLUS

CN Imidazo[1,2-a]pyrazine-6-carboxamide, 8-[[[2-ethyl-6-methylphenyl)methyl]amino]-2,3-dimethyl- (CA INDEX NAME)




RN 750571-48-3 CAPLUS

CN Imidazo[1,2-a]pyrazine-6-carboxamide, 8-[[[2-ethyl-6-methylphenyl)methyl]amino]-N,2,3-trimethyl- (CA INDEX NAME)




RN 750571-49-4 CAPLUS

CN Imidazo[1,2-a]pyrazine-6-carboxamide, 8-[[(2-ethyl-6-methylphenyl)methyl]amino]-N-(2-methoxyethyl)-2,3-dimethyl- (CA INDEX NAME)




RN 750571-50-7 CAPLUS

CN Imidazo[1,2-a]pyrazine-6-carboxamide, 8-[[(2-ethyl-6-methylphenyl)methyl]amino]-N-(2-hydroxyethyl)-2,3-dimethyl- (CA INDEX NAME)



RN 750571-52-9 CAPLUS


CN Imidazo[1,2-a]pyrazin-8-amine, N-[(2-ethyl-6-methylphenyl)methyl]-6-(methoxymethyl)-2,3-dimethyl-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 750571-53-0 CAPLUS

CN Imidazo[1,2-a]pyrazin-8-amine, N-[(2-ethyl-6-methylphenyl)methyl]-6-(methoxymethyl)-2,3-dimethyl- (CA INDEX NAME)



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 3 OF 29 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2004:267339 CAPLUS

DOCUMENT NUMBER: 140:303700

TITLE: Preparation and pharmaceutical compositions of novel imidazopyrazines as cyclin dependent kinase inhibitors
INVENTOR(S): Paruch, Kamil; Guzi, Timothy J.; Dwyer, Michael P.; Doll, Ronald J.; Girijavallabhan, Viyyoor M.; Mallams, Alan K.

PATENT ASSIGNEE(S): Schering Corporation, USA

SOURCE: PCT Int. Appl., 82 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004026877	A1	20040401	WO 2003-US29209	20030919 <--

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LU, LV, MA, MD, MG, MK, MN, MX, MZ, NI, NO, NZ, PG, PH, PL, PT, RO, RU, SC, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, UA, UZ, VC, VN, YU, ZA, ZM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

CA 2499756 A1 20040401 CA 2003-2499756 20030919 <--
AU 2003272476 A1 20040408 AU 2003-272476 20030919 <--
AU 2003272476 B2 20070705
EP 1543008 A1 20050622 EP 2003-754658 20030919 <--
EP 1543008 B1 20071107

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK

CN 1694886 A 20051109 CN 2003-825177 20030919 <--
JP 2006507253 T 20060302 JP 2004-537904 20030919 <--
AT 377600 T 20071115 AT 2003-754658 20030919 <--
NZ 538685 A 20080229 NZ 2003-538685 20030919 <--
ES 2293015 T3 20080316 ES 2003-754658 20030919 <--
MX 2005PA03120 A 20050622 MX 2005-PA3120 20050322 <--
ZA 2005002375 A 20050927 ZA 2005-2375 20050322 <--
HK 1072056 A1 20071221 HK 2005-105312 20050627 <--
AU 2007200401 A1 20070222 AU 2007-200401 20070131

PRIORITY APPLN. INFO.: US 2002-412997P P 20020923 <--
AU 2003-272476 A3 20030919
WO 2003-US29209 W 20030919

OTHER SOURCE(S): MARPAT 140:303700


IT 676359-71-0P 676359-82-3P 676359-86-7P
676359-88-9P 676359-92-5P 676359-94-7P
676359-98-1P 676360-00-2P 676360-02-4P
676360-05-7P 676360-09-1P 676360-11-5P
676360-29-5P 676360-37-5P 676360-41-1P
676360-43-3P

RL: CPN (Combinatorial preparation); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); CMBI (Combinatorial study); PREP (Preparation); USES (Uses)

(drug candidate; combinatorial preparation of a library of imidazopyrazines as cyclin dependent kinase inhibitors)


RN 676359-71-0 CAPLUS

CN Imidazo[1,2-a]pyrazin-8-amine, 3-bromo-6-(2-chlorophenyl)-N-(cyclopropylmethyl)- (CA INDEX NAME)




RN 676359-82-3 CAPLUS

CN Imidazo[1,2-a]pyrazin-8-amine, 3-bromo-6-(2-chlorophenyl)-N-[(tetrahydro-2-furanyl)methyl]- (CA INDEX NAME)




RN 676359-86-7 CAPLUS

CN Imidazo[1,2-a]pyrazin-8-amine, 3-bromo-6-(2-chlorophenyl)-N-(2-thienylmethyl)- (CA INDEX NAME)




RN 676359-88-9 CAPLUS

CN Imidazo[1,2-a]pyrazin-8-amine, 3-bromo-6-(2-chlorophenyl)-N-(cyclohexylmethyl)- (CA INDEX NAME)




RN 676359-92-5 CAPLUS

CN Imidazo[1,2-a]pyrazin-8-amine, 3-bromo-6-(2-chlorophenyl)-N-(1-phenylethyl)- (CA INDEX NAME)




RN 676359-94-7 CAPLUS

CN Imidazo[1,2-a]pyrazin-8-amine, 3-bromo-6-(2-chlorophenyl)-N-(2-phenylethyl)- (CA INDEX NAME)




RN 676359-98-1 CAPLUS

CN Imidazo[1,2-a]pyrazin-8-amine, 3-bromo-6-(2-chlorophenyl)-N-(2-phenylpropyl)- (CA INDEX NAME)




RN 676360-00-2 CAPLUS

CN Imidazo[1,2-a]pyrazin-8-amine, 3-bromo-6-(2-chlorophenyl)-N-[(3-methoxyphenyl)methyl]- (CA INDEX NAME)




RN 676360-02-4 CAPLUS

CN Imidazo[1,2-a]pyrazin-8-amine, 3-bromo-6-(2-chlorophenyl)-N-[(3-chlorophenyl)methyl]- (CA INDEX NAME)




RN 676360-05-7 CAPLUS

CN Imidazo[1,2-a]pyrazin-8-amine, 3-bromo-6-(2-chlorophenyl)-N-[1-(4-chlorophenyl)ethyl]- (CA INDEX NAME)




RN 676360-09-1 CAPLUS

CN Imidazo[1,2-a]pyrazin-8-amine, 3-bromo-6-(2-chlorophenyl)-N-[[4-(trifluoromethyl)phenyl]methyl]- (CA INDEX NAME)




RN 676360-11-5 CAPLUS

CN Imidazo[1,2-a]pyrazin-8-amine, 3-bromo-6-(2-chlorophenyl)-N-(2,2-diphenylethyl)- (CA INDEX NAME)



RN 676360-29-5 CAPLUS


CN Imidazo[1,2-a]pyrazin-8-amine, 3-bromo-6-(2-chlorophenyl)-N-(3-pyridinylmethyl)- (CA INDEX NAME)



RN 676360-37-5 CAPLUS


CN Imidazo[1,2-a]pyrazin-8-amine, 3-bromo-6-(2-chlorophenyl)-N-[(1-ethyl-2-

pyrrolidinyl)methyl]- (CA INDEX NAME)




RN 676360-41-1 CAPLUS

CN Imidazo[1,2-a]pyrazin-8-amine, 3-bromo-6-(2-chlorophenyl)-N-[2-(1-methyl-2-pyrrolidinyl)ethyl]- (CA INDEX NAME)




RN 676360-43-3 CAPLUS


CN Imidazo[1,2-a]pyrazin-8-amine, 3-bromo-6-(2-chlorophenyl)-N-[2-(4-morpholinyl)ethyl]- (CA INDEX NAME)



IT 676359-53-8P 676360-96-6P
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (drug candidate; preparation of imidazopyrazines as cyclin dependent kinase inhibitors)
 RN 676359-53-8 CAPLUS
 CN Ethanone, 1-[6-phenyl-8-[(3-pyridinylmethyl)amino]imidazo[1,2-a]pyrazin-3-yl]- (CA INDEX NAME)



RN 676360-96-6 CAPLUS
 CN Imidazo[1,2-a]pyrazin-8-amine, 3-iodo-6-phenyl-N-(3-pyridinylmethyl)- (CA INDEX NAME)




IT 676359-47-0P 676359-49-2P 676359-51-6P
 676359-55-0P 676359-56-1P 676359-58-3P
 676359-60-7P 676359-65-2P 676359-67-4P
 676359-70-9P 676360-59-1P 676360-61-5P
 676360-63-7P 676360-65-9P 676360-67-1P
 676360-69-3P 676360-76-2P 676360-78-4P
 676360-80-8P 676360-82-0P 676360-84-2P
 676360-86-4P 676360-91-1P 676361-00-5P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of imidazopyrazines as cyclin dependent kinase inhibitors)


RN 676359-47-0 CAPLUS

CN Imidazo[1,2-a]pyrazin-8-amine, 3,6-diphenyl-N-(3-pyridinylmethyl)- (CA INDEX NAME)




RN 676359-49-2 CAPLUS


CN Imidazo[1,2-a]pyrazin-8-amine, 6-phenyl-N-(3-pyridinylmethyl)-3-(3-thienyl)- (CA INDEX NAME)




RN 676359-51-6 CAPLUS
 CN Imidazo[1,2-a]pyrazin-8-amine, 3-ethenyl-6-phenyl-N-(3-pyridinylmethyl)-
 (CA INDEX NAME)




RN 676359-55-0 CAPLUS
 CN Imidazo[1,2-a]pyrazine-3-methanol, α,α -dimethyl-6-phenyl-8-[(3-pyridinylmethyl)amino]- (CA INDEX NAME)




RN 676359-56-1 CAPLUS
 CN Imidazo[1,2-a]pyrazin-8-amine, 3-methyl-N-(3-pyridinylmethyl)- (CA INDEX NAME)




RN 676359-58-3 CAPLUS
 CN Imidazo[1,2-a]pyrazin-8-amine, 3-methyl-N-(phenylmethyl)- (CA INDEX NAME)



RN 676359-60-7 CAPLUS
 CN Imidazo[1,2-a]pyrazin-8-amine, 3-methyl-N-[2-(4-pyridinyl)ethyl]- (CA INDEX NAME)




RN 676359-65-2 CAPLUS
 CN Imidazo[1,2-a]pyrazin-8-amine, 3-methyl-N-(4-pyridinylmethyl)- (CA INDEX NAME)




RN 676359-67-4 CAPLUS

CN Imidazo[1,2-a]pyrazin-8-amine, N-(diphenylmethyl)-3-methyl- (CA INDEX NAME)




RN 676359-70-9 CAPLUS

CN Imidazo[1,2-a]pyrazin-8-amine, 3-bromo-6-phenyl-N-(5-pyrimidinylmethyl)- (CA INDEX NAME)




RN 676360-59-1 CAPLUS

CN 2-Piperidineethanol, 1-[3-bromo-8-[(3-pyridinylmethyl)amino]imidazo[1,2-a]pyrazin-6-yl]- (CA INDEX NAME)




RN 676360-61-5 CAPLUS

CN Cyclohexanol, 2-[[3-bromo-8-[(3-pyridinylmethyl)amino]imidazo[1,2-a]pyrazin-6-yl]amino]- (CA INDEX NAME)




RN 676360-63-7 CAPLUS

CN Cyclohexanemethanol, 2-[[3-bromo-8-[(3-pyridinylmethyl)amino]imidazo[1,2-a]pyrazin-6-yl]amino]- (CA INDEX NAME)




RN 676360-65-9 CAPLUS

CN 1-Butanol, 2-[[3-bromo-8-[(3-pyridinylmethyl)amino]imidazo[1,2-a]pyrazin-6-yl]amino]-3-methyl- (CA INDEX NAME)




RN 676360-67-1 CAPLUS

CN Imidazo[1,2-a]pyrazin-8-amine, 3-bromo-6-phenyl-N-(4-pyridinylmethyl)-
(CA INDEX NAME)




RN 676360-69-3 CAPLUS

CN Imidazo[1,2-a]pyrazin-8-amine, 3-bromo-6-phenyl-N-(3-pyridinylmethyl)-
(CA INDEX NAME)




RN 676360-76-2 CAPLUS

CN Imidazo[1,2-a]pyrazin-8-amine, 3-bromo-6-phenyl-N-[2-(4-pyridinyl)ethyl]-
(CA INDEX NAME)




RN 676360-78-4 CAPLUS

CN Imidazo[1,2-a]pyrazin-8-amine, 3-bromo-6-phenyl-N-[2-(3-pyridinyl)ethyl]-
(CA INDEX NAME)




RN 676360-80-8 CAPLUS

CN Imidazo[1,2-a]pyrazin-8-amine, 3-iodo-6-phenyl-N-(4-pyridinylmethyl)-
(CA INDEX NAME)




RN 676360-82-0 CAPLUS

CN Imidazo[1,2-a]pyrazin-8-amine, 3-bromo-6-(2-chlorophenyl)-N-(4-pyridinylmethyl)-
(CA INDEX NAME)




RN 676360-84-2 CAPLUS

CN Imidazo[1,2-a]pyrazin-8-amine, 6-(2-chlorophenyl)-3-iodo-N-(4-pyridinylmethyl)- (CA INDEX NAME)




RN 676360-86-4 CAPLUS


CN Imidazo[1,2-a]pyrazin-8-amine, 6-(2-chlorophenyl)-3-iodo-N-(3-pyridinylmethyl)- (CA INDEX NAME)



RN 676360-91-1 CAPLUS
CN Imidazo[1,2-a]pyrazin-8-amine, 3-chloro-6-(2-chlorophenyl)-N-(3-pyridinylmethyl)- (CA INDEX NAME)



RN 676361-00-5 CAPLUS
CN Imidazo[1,2-a]pyrazin-8-amine, 3-bromo-6-phenyl-N-[(6-(trifluoromethyl)-3-pyridinyl)methyl]- (CA INDEX NAME)



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 4 OF 29 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2004:267246 CAPLUS

DOCUMENT NUMBER: 140:303696

TITLE: Preparation and pharmaceutical compositions of novel imidazopyrazines as cyclin dependent kinase inhibitors
Paruch, Kamil; Guzi, Timothy J.; Dwyer, Michael P.; Doll, Ronald J.; Girijavallabhan, Viyyoor M.

PATENT ASSIGNEE(S): Schering Corporation, USA

SOURCE: PCT Int. Appl., 46 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
------------	------	------	-----------------	------

WO 2004026310	A1	20040401	WO 2003-US29456	20030919 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2499874	A1	20040401	CA 2003-2499874	20030919 <--
AU 2003275031	A1	20040408	AU 2003-275031	20030919 <--
US 20040072835	A1	20040415	US 2003-666424	20030919 <--
US 7186740	B2	20070306		
EP 1542693	A1	20050622	EP 2003-759300	20030919 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
CN 1694706	A	20051109	CN 2003-825102	20030919 <--
JP 2006503838	T	20060202	JP 2004-538213	20030919 <--
NZ 538686	A	20080131	NZ 2003-538686	20030919 <--
MX 2005PA03119	A	20050622	MX 2005-PA3119	20050322 <--
ZA 2005002380	A	20050927	ZA 2005-2380	20050322 <--
US 20070155751	A1	20070705	US 2007-680929	20070301 <--
PRIORITY APPLN. INFO.:			US 2002-412906P	P 20020923 <--
			US 2003-666424	A3 20030919
			WO 2003-US29456	W 20030919

OTHER SOURCE(S): MARPAT 140:303696


IT 676132-50-6P 676132-51-7P 676132-52-8P
 676132-53-9P 676132-54-0P 676132-55-1P
 676132-56-2P 676132-57-3P 676132-58-4P
 676132-59-5P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of novel imidazopyrazines as cyclin dependent kinase inhibitors)


RN 676132-50-6 CAPLUS

CN Imidazo[1,2-a]pyrazin-8-amine, 6-methyl-N-(3-pyridinylmethyl)- (CA INDEX NAME)




RN 676132-51-7 CAPLUS


CN Imidazo[1,2-a]pyrazin-8-amine, 6-(1,1-dimethylethyl)-N-(3-pyridinylmethyl)- (CA INDEX NAME)




RN 676132-52-8 CAPLUS
 CN Imidazo[1,2-a]pyrazin-8-amine, 6-ethyl-N-(3-pyridinylmethyl)- (CA INDEX NAME)



RN 676132-53-9 CAPLUS
 CN Imidazo[1,2-a]pyrazin-8-amine, 6-(cyclohexylmethyl)-N-(3-pyridinylmethyl)- (CA INDEX NAME)




RN 676132-54-0 CAPLUS
 CN Imidazo[1,2-a]pyrazin-8-amine, 6-(phenylmethyl)-N-(3-pyridinylmethyl)- (CA INDEX NAME)




RN 676132-55-1 CAPLUS

CN Imidazo[1,2-a]pyrazin-8-amine, 3-bromo-6-methyl-N-(3-pyridinylmethyl)- (CA INDEX NAME)




RN 676132-56-2 CAPLUS

CN Imidazo[1,2-a]pyrazin-8-amine, 3-bromo-6-(1,1-dimethylethyl)-N-(3-pyridinylmethyl)- (CA INDEX NAME)




RN 676132-57-3 CAPLUS

CN Imidazo[1,2-a]pyrazin-8-amine, 3-bromo-6-ethyl-N-(3-pyridinylmethyl)- (CA INDEX NAME)




RN 676132-58-4 CAPLUS

CN Imidazo[1,2-a]pyrazin-8-amine, 3-bromo-6-(cyclohexylmethyl)-N-(3-pyridinylmethyl)- (CA INDEX NAME)



RN 676132-59-5 CAPLUS

CN Imidazo[1,2-a]pyrazin-8-amine, 3-bromo-6-(phenylmethyl)-N-(3-pyridinylmethyl)- (CA INDEX NAME)



REFERENCE COUNT:

1

THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 5 OF 29 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2004:220337 CAPLUS

DOCUMENT NUMBER: 140:270878

TITLE: Kinase-modulating 6-aryl-imidazo[1,2-a]pyrazin-8-ylamines, method of their preparation, and method of their use, e.g., against cancer cells

INVENTOR(S): Desimone, Robert W.; Pippin, Douglas A.; Darrow, James W.; Mitchell, Scott A.; Currie, Kevin S.

PATENT ASSIGNEE(S): Cellular Genomics, Inc., USA

SOURCE: PCT Int. Appl., 74 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1


PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004022562	A1	20040318	WO 2003-US28329	20030909 <--
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW			
R:	GH, GM, KE, LE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
AU 2003270489	A1	20040329	AU 2003-270489	20030909 <--
US 20040067951	A1	20040408	US 2003-658121	20030909 <--
US 7312341	B2	20071225		
PRIORITY APPLN. INFO.:			US 2002-409161P	P 20020909 <--
			WO 2003-US28329	W 20030909
OTHER SOURCE(S):	MARPAT 140:270878			
IT 618455-54-2P, 1-[4-[8-(2-Methoxybenzylamino)imidazo[1,2-a]pyrazin-6-yl]phenyl]-3-phenylurea 618455-60-0P, (2-Methoxybenzyl) [6-[3-(4-methoxybenzylamino)phenyl]imidazo[1,2-a]pyrazin-8-yl]amine 618455-66-6P, 1-(2-Chlorophenyl)-3-[4-[8-(2-methoxybenzylamino)imidazo[1,2-a]pyrazin-6-yl]phenyl]urea 618455-69-9P, 1-[4-[8-(2-Methoxybenzylamino)imidazo[1,2-a]pyrazin-6-yl]phenyl]-3-(2-methoxyphenyl)urea 618455-71-3P, 1-[4-[8-(2-Methoxybenzylamino)imidazo[1,2-a]pyrazin-6-yl]phenyl]-3-(3-methoxyphenyl)urea 673857-09-5P, 3-Methoxy-N-[3-[8-(2-methoxybenzylamino)imidazo[1,2-a]pyrazin-6-yl]phenyl]benzamide 673857-10-8P, 2-Methoxy-N-[3-[8-(2-methoxybenzylamino)imidazo[1,2-a]pyrazin-6-yl]phenyl]benzamide 673857-12-0P, 1-(3-Chloro-4-fluorophenyl)-3-[3-[8-(pyridin-2-ylmethyl)amino]imidazo[1,2-a]pyrazin-6-yl]phenyl]urea 673857-13-1P, 1-(4-Chlorophenyl)-3-[3-[8-(pyridin-3-ylmethyl)amino]imidazo[1,2-a]pyrazin-6-yl]phenyl]urea 673857-14-2P, 1-(3-Chloro-4-fluorophenyl)-3-[3-[8-(pyridin-3-ylmethyl)amino]imidazo[1,2-a]pyrazin-6-yl]phenyl]urea 673857-15-3P, 1-(4-Chlorophenyl)-3-[3-[8-(pyridin-4-ylmethyl)amino]imidazo[1,2-a]pyrazin-6-yl]phenyl]urea 673857-16-4P, 1-[3-[8-(Pyridin-4-ylmethyl)amino]imidazo[1,2-a]pyrazin-6-yl]phenyl]-3-(3-trifluoromethylphenyl)urea 673857-17-5P, 1-(3-Chloro-4-fluorophenyl)-3-[3-[8-(pyridin-4-ylmethyl)amino]imidazo[1,2-a]pyrazin-6-yl]phenyl]urea 673857-20-0P, 1-(4-Chlorophenyl)-3-[3-[8-(pyridin-2-ylmethyl)amino]imidazo[1,2-a]pyrazin-6-yl]phenyl]urea 673857-21-1P, 1-[3-[8-(Pyridin-2-ylmethyl)amino]imidazo[1,2-a]pyrazin-6-yl]phenyl]-3-(3-trifluoromethylphenyl)urea				
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)				
(drug candidate; preparation of arylimidazopyrazinylamines as kinase				

modulators)


RN 618455-54-2 CAPLUS

CN Urea, N-[4-[8-[[(2-methoxyphenyl)methyl]amino]imidazo[1,2-a]pyrazin-6-yl]phenyl]-N'-phenyl- (CA INDEX NAME)




RN 618455-60-0 CAPLUS

CN Imidazo[1,2-a]pyrazin-8-amine, N-[(2-methoxyphenyl)methyl]-6-[3-[[(4-methoxyphenyl)methyl]amino]phenyl]- (CA INDEX NAME)




RN 618455-66-6 CAPLUS

CN Urea, N-(2-chlorophenyl)-N'-[4-[8-[[(2-methoxyphenyl)methyl]amino]imidazo[1,2-a]pyrazin-6-yl]phenyl]- (CA INDEX NAME)




RN 618455-69-9 CAPLUS

CN Urea, N-(2-methoxyphenyl)-N'-[4-[8-[(2-methoxyphenyl)methyl]amino]imidazo
[1,2-a]pyrazin-6-yl]phenyl]- (CA INDEX NAME)




RN 618455-71-3 CAPLUS

CN Urea, N-(3-methoxyphenyl)-N'-[4-[8-[(2-methoxyphenyl)methyl]amino]imidazo
[1,2-a]pyrazin-6-yl]phenyl]- (CA INDEX NAME)




RN 673857-09-5 CAPLUS

CN Benamide, 3-methoxy-N-[3-[8-[(2-methoxyphenyl)methyl]amino]imidazo[1,2-a]pyrazin-6-yl]phenyl]- (CA INDEX NAME)




RN 673857-10-8 CAPLUS

CN Benamide, 2-methoxy-N-[3-[8-[(2-methoxyphenyl)methyl]amino]imidazo[1,2-a]pyrazin-6-yl]phenyl]- (CA INDEX NAME)




RN 673857-12-0 CAPLUS

CN Urea, N-(3-chloro-4-fluorophenyl)-N'-[3-[8-[(2-pyridinylmethyl)amino]imidazo[1,2-a]pyrazin-6-yl]phenyl]- (CA INDEX NAME)




RN 673857-13-1 CAPLUS

CN Urea, N-(4-chlorophenyl)-N'-[3-[8-[(3-pyridinylmethyl)amino]imidazo[1,2-a]pyrazin-6-yl]phenyl]- (CA INDEX NAME)




RN 673857-14-2 CAPLUS

CN Urea, N-(3-chloro-4-fluorophenyl)-N'-[3-[8-[(3-pyridinylmethyl)amino]imidazo[1,2-a]pyrazin-6-yl]phenyl]- (CA INDEX NAME)




RN 673857-15-3 CAPLUS

CN Urea, N-(4-chlorophenyl)-N'-[3-[8-[(4-pyridinylmethyl)amino]imidazo[1,2-a]pyrazin-6-yl]phenyl]- (CA INDEX NAME)




RN 673857-16-4 CAPLUS

CN Urea, N-[3-[8-[(4-pyridinylmethyl)amino]imidazo[1,2-a]pyrazin-6-yl]phenyl]-N'-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 673857-17-5 CAPLUS

CN Urea, N-(3-chloro-4-fluorophenyl)-N'-[3-[8-[(4-pyridinylmethyl)amino]imidazo[1,2-a]pyrazin-6-yl]phenyl]- (CA INDEX NAME)




RN 673857-20-0 CAPLUS

CN Urea, N-(4-chlorophenyl)-N'-[3-[8-[(2-pyridinylmethyl)amino]imidazo[1,2-a]pyrazin-6-yl]phenyl]- (CA INDEX NAME)



RN 673857-21-1 CAPLUS

CN Urea, N-[3-[8-[(2-pyridinylmethyl)amino]imidazo[1,2-a]pyrazin-6-yl]phenyl]-N'-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)




REFERENCE COUNT:

1

THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L5 ANSWER 6 OF 29 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCSSION NUMBER: 2003:855931 CAPLUS
 DOCUMENT NUMBER: 139:350757
 TITLE: Preparation of imidazo[1,2-a]pyrazin-8-ylamines as
 AKT-1 kinase inhibitors
 INVENTOR(S): Desimone, Robert Walter, Jr.; Pippin, Douglas A.;
 Darrow, James W.
 PATENT ASSIGNEE(S): Cellular Genomics, Inc., USA
 SOURCE: PCT Int. Appl., 52 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003089434	A2	20031030	WO 2003-US12222	20030421 <--
WO 2003089434	A3	20040115		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
CA 2482991	A1	20031030	CA 2003-2482991	20030421 <--
AU 2003221731	A1	20031103	AU 2003-221731	20030421 <--
US 20030212073	A1	20031113	US 2003-419682	20030421 <--
US 6919340	B2	20050719		
BR 2003009398	A	20050201	BR 2003-9398	20030421 <--
EP 1509526	A2	20050302	EP 2003-718470	20030421 <--
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			
CN 1668619	A	20050914	CN 2003-814467	20030421 <--
JP 2005530739	T	20051013	JP 2003-586154	20030421 <--
MX 2004PA10288	A	20050517	MX 2004-PA10288	20041018 <--
NO 2004004974	A	20041116	NO 2004-4974	20041116 <--
PRIORITY APPLN. INFO.:			US 2002-374213P	P 20020419 <--
			WO 2003-US12222	W 20030421
OTHER SOURCE(S):	MARPAT 139:350757			
IT	618455-08-6P 618455-13-3P 618455-19-9P 618455-25-7P 618455-36-0P 618455-41-7P 618455-47-3P 618455-50-8P 618455-54-2P 618455-57-5P 618455-60-0P 618455-63-3P 618455-66-6P 618455-69-9P 618455-71-3P 618455-82-6P			
RL:	PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)			
	(preparation of imidazo[1,2-a]pyrazin-8-ylamines as AKT-1 kinase inhibitors)			
RN	618455-08-6 CAPLUS			
CN	Urea, N-(4-chlorophenyl)-N'-[3-[8-[(4-chlorophenyl)methyl]amino]imidazo[1,2-a]pyrazin-6-yl]phenyl]- (CA INDEX NAME)			




RN 618455-13-3 CAPLUS

CN Urea, N-(4-chlorophenyl)-N'-[3-[8-[[3-(3-chlorophenyl)methyl]amino]imidazo[1,2-a]pyrazin-6-yl]phenyl]- (CA INDEX NAME)




RN 618455-19-9 CAPLUS


CN Urea, N-(4-chlorophenyl)-N'-[4-[8-[[4-(4-chlorophenyl)methyl]amino]imidazo[1,2-a]pyrazin-6-yl]phenyl]- (CA INDEX NAME)



RN 618455-25-7 CAPLUS
 CN Urea, N-(4-chlorophenyl)-N'-[4-[8-[(3-chlorophenyl)methyl]amino]imidazo[1,2-a]pyrazin-6-yl]phenyl]- (CA INDEX NAME)




RN 618455-36-0 CAPLUS
 CN Imidazo[1,2-a]pyrazin-8-amine, N-(cyclopropylmethyl)-6-(4-phenoxyphenyl)- (CA INDEX NAME)




RN 618455-41-7 CAPLUS

CN Imidazo[1,2-a]pyrazin-8-amine, N-[(2-methoxyphenyl)methyl]-6-(4-phenoxyphenyl)- (CA INDEX NAME)




RN 618455-47-3 CAPLUS

CN Imidazo[1,2-a]pyrazin-8-amine, N-(1,3-benzodioxol-5-ylmethyl)-6-(4-phenoxyphenyl)- (CA INDEX NAME)



RN 618455-50-8 CAPLUS


CN Imidazo[1,2-a]pyrazin-8-amine, 6-[4-(chloromethyl)phenyl]-N-[(2-methoxyphenyl)methyl]- (CA INDEX NAME)



RN 618455-54-2 CAPLUS


CN Urea, N-[4-[8-[[[2-methoxyphenyl)methyl]amino]imidazo[1,2-a]pyrazin-6-

yl]phenyl]-N'-phenyl- (CA INDEX NAME)




RN 618455-57-5 CAPLUS

CN Imidazo[1,2-a]pyrazin-8-amine, N-[(2-methoxyphenyl)methyl]-6-[4-[(4-methoxyphenyl)methyl]amino]phenyl]- (CA INDEX NAME)



RN 618455-60-0 CAPLUS


CN Imidazo[1,2-a]pyrazin-8-amine, N-[(2-methoxyphenyl)methyl]-6-[3-[(4-methoxyphenyl)methyl]amino]phenyl]- (CA INDEX NAME)



RN 618455-63-3 CAPLUS


CN Urea, N-[3-[8-[(2-methoxyphenyl)methyl]amino]imidazo[1,2-a]pyrazin-6-

yl]phenyl]-N'-phenyl- (CA INDEX NAME)




RN 618455-66-6 CAPLUS

CN Urea, N-(2-chlorophenyl)-N'-[4-[8-[[2-methoxyphenyl)methyl]amino]imidazo[1,2-a]pyrazin-6-yl]phenyl]- (CA INDEX NAME)




RN 618455-69-9 CAPLUS

CN Urea, N-(2-methoxyphenyl)-N'-[4-[8-[[2-methoxyphenyl)methyl]amino]imidazo[1,2-a]pyrazin-6-yl]phenyl]- (CA INDEX NAME)




RN 618455-71-3 CAPLUS

CN Urea, N-(3-methoxyphenyl)-N'-[4-[8-[(2-methoxyphenyl)methyl]amino]imidazo[1,2-a]pyrazin-6-yl]phenyl- (CA INDEX NAME)



RN 618455-82-6 CAPLUS


CN Benzamide, N-[4-[3-methoxy-8-[(2-methoxyphenyl)methyl]amino]imidazo[1,2-a]pyrazin-6-yl]phenyl- (CA INDEX NAME)




ACCESSION NUMBER: 2003:818425 CAPLUS
 DOCUMENT NUMBER: 139:337987
 TITLE: Preparation of imidazothienopyrazines for treatment of inflammatory and immune diseases.
 INVENTOR(S): Belema, Makonen; Bunker, Amy; Nguyen, Van; Beaulieu, Francis; Ouellet, Carl; Marinier, Anne; Roy, Stephan; Yang, Xuejie; Qiu, Yuping; Zhang, Yunhui; Martel, Alain; Zusi, Christopher
 PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA
 SOURCE: PCT Int. Appl., 268 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003084959	A1	20031016	WO 2003-US9549	20030327 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2003222106	A1	20031020	AU 2003-222106	20030327 <--
US 20040058930	A1	20040325	US 2003-400387	20030327 <--
US 6933294	B2	20050823		
EP 1490371	A1	20041229	EP 2003-718092	20030327 <--
EP 1490371	B1	20070815		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
AT 370145	T	20070915	AT 2003-718092	20030327 <--
ES 2291628	T3	20080301	ES 2003-718092	20030327 <--
PRIORITY APPLN. INFO.:			US 2002-369698P	P 20020403 <--
			WO 2003-US9549	W 20030327

OTHER SOURCE(S): MARPAT 139:337987
 IT 615535-52-9P 615535-53-0P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of imidazothienopyrazines for treatment of inflammatory and immune diseases)
 RN 615535-52-9 CAPLUS
 CN Imidazo[1,2-a]pyrazin-8-amine, 6-bromo-3-methyl-N-[2-(1-piperidinyl)ethyl]-(CA INDEX NAME)



RN 615535-53-0 CAPLUS
 CN Imidazo[1,2-a]pyrazin-8-amine, 3-methyl-N-[2-(1-piperidinyl)ethyl]-6-
 [(trimethylsilyl)ethynyl]- (9CI) (CA INDEX NAME)




REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 8 OF 29 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2002:594712 CAPLUS
 DOCUMENT NUMBER: 137:150267
 TITLE: Methods using pyrazine compounds and pyridine
 compounds for inhibiting JAK kinases, compound
 preparation, and therapeutic use
 Burns, Christopher John; Wilks, Andrew Frederick
 INVENTOR(S): Cytopia Pty. Ltd., Australia
 PATENT ASSIGNEE(S): PCT Int. Appl., 92 pp.
 SOURCE: CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002060492	A1	20020808	WO 2002-AU89	20020130 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,				

CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
 GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
 LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
 PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ,
 UA, UG, US, UZ, VN, YU, ZA, ZM, ZW
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH,
 CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR,
 BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
 CA 2436487 A1 20020808 CA 2002-2436487 20020130 <--
 AU 2002226197 A1 20020812 AU 2002-226197 20020130 <--
 EP 1363702 A1 20031126 EP 2002-715984 20020130 <--
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR
 JP 2004528295 T 20040916 JP 2002-560683 20020130 <--
 US 20040102455 A1 20040527 US 2003-470955 20030730 <--
 US 20060069084 A1 20060330 US 2005-223633 20050909 <--
 PRIORITY APPLN. INFO.: AU 2001-2792 A 20010130 <--
 AU 2001-2793 A 20010130 <--
 WO 2002-AU89 W 20020130 <--
 US 2003-470955 A3 20030730

OTHER SOURCE(S): MARPAT 137:150267
 IT 445263-60-5 445263-61-6 445263-76-3
 445263-77-4 445263-96-7 445263-97-8
 445264-10-8 445264-14-2 445264-15-3
 445264-22-2 445264-30-2 445264-31-3
 445264-32-4 445264-38-0
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
 (Biological study); USES (Uses)
 (pyrazine compds. and pyridine compds. for inhibiting JAK kinases,
 compound preparation, and therapeutic use)
 RN 445263-60-5 CAPLUS
 CN Imidazo[1,2-a]pyrazin-8-amine, 6-(2-fluorophenyl)-N-(2-pyridinylmethyl)-
 (CA INDEX NAME)




RN 445263-61-6 CAPLUS
 CN Imidazo[1,2-a]pyrazin-8-amine, N-(2-pyridinylmethyl)-6-(3,4,5-
 trimethoxyphenyl)- (CA INDEX NAME)




RN 445263-76-3 CAPLUS

CN Imidazo[1,2-a]pyrazin-8-amine, 6-[3,5-bis(trifluoromethyl)phenyl]-N-[(tetrahydro-2H-pyran-4-yl)methyl]- (CA INDEX NAME)




RN 445263-77-4 CAPLUS

CN Imidazo[1,2-a]pyrazin-8-amine, 6-phenyl-N-(4-pyridinylmethyl)- (CA INDEX NAME)




RN 445263-96-7 CAPLUS

CN Imidazo[1,2-a]pyrazin-8-amine, 6-(3-pyridinyl)-N-[2-(4-pyridinyl)ethyl]-
(CA INDEX NAME)




RN 445263-97-8 CAPLUS

CN Imidazo[1,2-a]pyrazin-8-amine, 6-(2-furanyl)-N-[2-(3-pyridinyl)ethyl]-
(CA INDEX NAME)




RN 445264-10-8 CAPLUS


CN Imidazo[1,2-a]pyrazin-8-amine, 6-(2-chlorophenyl)-N-(2-pyridinylmethyl)-
(CA INDEX NAME)




RN 445264-14-2 CAPLUS
 CN Imidazo[1,2-a]pyrazin-8-amine, 6-(1-hexenyl)-N-(3-pyridinylmethyl)- (9CI)
 (CA INDEX NAME)



RN 445264-15-3 CAPLUS
 CN Imidazo[1,2-a]pyrazin-8-amine, 6-(1-hexenyl)-N-(4-pyridinylmethyl)- (9CI)
 (CA INDEX NAME)




RN 445264-22-2 CAPLUS
 CN Phenol, 5-[8-[(cyclopropylmethyl)amino]imidazo[1,2-a]pyrazin-6-yl]-2-methoxy- (CA INDEX NAME)




RN 445264-30-2 CAPLUS

CN Benzenepropanoic acid, 4-[8-[[2-(4-pyridinyl)ethyl]amino]imidazo[1,2-a]pyrazin-6-yl]- (CA INDEX NAME)




RN 445264-31-3 CAPLUS

CN Imidazo[1,2-a]pyrazin-8-amine, 6-(2-fluorophenyl)-N-[2-(3-pyridinyl)ethyl]- (CA INDEX NAME)




RN 445264-32-4 CAPLUS

CN Benzenepropanoic acid, 4-[8-[(2-furanylmethyl)amino]imidazo[1,2-a]pyrazin-6-yl]- (CA INDEX NAME)



RN 445264-38-0 CAPLUS
 CN Imidazo[1,2-a]pyrazin-8-amine, 6-(1H-indol-5-yl)-N-(phenylmethyl)- (CA INDEX NAME)



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 9 OF 29 CAPLUS COPYRIGHT 2008 ACS ON STN
 ACCESSION NUMBER: 1999:375549 CAPLUS
 DOCUMENT NUMBER: 131:19022
 TITLE: Preparation of heterocyclic compounds for inhibition of gastric acid secretion
 INVENTOR(S): Amin, Kosrat; Dahlstrom, Mikael; Nordberg, Peter; Starke, Ingemar
 PATENT ASSIGNEE(S): Astra Aktiebolag, Swed.
 SOURCE: PCT Int. Appl., 34 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9928322	A1	19990610	WO 1998-SE2091	19981118 <--
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
ZA 9810468	A	19990521	ZA 1998-10468	19981116 <--
TW 515798	B	20030101	TW 1998-87118942	19981116 <--
CA 2311798	A1	19990610	CA 1998-2311798	19981118 <--
AU 9913565	A	19990616	AU 1999-13565	19981118 <--
AU 752187	B2	20020912		
BR 9814755	A	20001003	BR 1998-14755	19981118 <--
EP 1042324	A1	20001011	EP 1998-957270	19981118 <--

EP 1042324 B1 20030226
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, LT, LV, FI, RO
 TR 200001530 T2 20001121 TR 2000-1530 19981118 <--
 HU 2001000601 A2 20010928 HU 2001-601 19981118 <--
 HU 2001000601 A3 20021028
 EE 200000315 A 20011015 EE 2000-315 19981118 <--
 EE 4060 B1 20030616
 JP 2001525322 T 20011211 JP 2000-523214 19981118 <--
 NZ 504355 A 20011221 NZ 1998-504355 19981118 <--
 AT 233263 T 20030315 AT 1998-957270 19981118 <--
 PT 1042324 T 20030630 PT 1998-957270 19981118 <--
 ES 2191356 T3 20030901 ES 1998-957270 19981118 <--
 CZ 292349 B6 20030917 CZ 2000-1947 19981118 <--
 SK 283904 B6 20040406 SK 2000-674 19981118 <--
 RU 2241000 C2 20041127 RU 2000-113729 19981118 <--
 US 6518270 B1 20030211 US 2000-194823 20000208 <--
 MX 2000PA05111 A 20011203 MX 2000-PA5111 20000524 <--
 NO 2000002721 A 20000728 NO 2000-2721 20000526 <--
 NO 315704 B1 20031013
 HK 1030216 A1 20030620 HK 2001-101145 20010216 <--
 PRIORITY APPLN. INFO.: SE 1997-4404 A 19971128 <--
 WO 1998-SE2091 W 19981118 <--


OTHER SOURCE(S): MARPAT 131:19022

IT 226721-20-6P 226721-23-9P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of heterocyclic compds. for inhibition of gastric acid secretion)


RN 226721-20-6 CAPLUS

CN Imidazo[1,2-a]pyrazine-8-amine, N-[(2,6-dimethylphenyl)methyl]-2,3-dimethyl-
 (CA INDEX NAME)



RN 226721-23-9 CAPLUS

CN Imidazo[1,2-a]pyrazine, 8-[(2,6-dimethylphenyl)methoxy]-2,3-dimethyl- (CA INDEX NAME)



REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 10 OF 29 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1997:144995 CAPLUS

DOCUMENT NUMBER: 126:139485

TITLE: Antiulcer Agents. 6. Analysis of the in Vitro Biochemical and in Vivo Gastric Antisecretory Activity of Substituted Imidazo[1,2-a]pyridines and Related Analogs Using Comparative Molecular Field Analysis and Hypothetical Active Site Lattice Methodologies
AUTHOR(S): Kaminski, James J.; Doweyko, Arthur M.
CORPORATE SOURCE: Schering-Plough Research Institute, Kenilworth, NJ, 07033, USA

SOURCE: Journal of Medicinal Chemistry (1997), 40(4), 427-436

CODEN: JMCMAR; ISSN: 0022-2623

PUBLISHER: American Chemical Society

DOCUMENT TYPE: Journal

LANGUAGE: English


IT 85333-40-0P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation and structure-activity relations of substituted imidazopyridines and related analogs as antiulcer agents)

RN 85333-40-0 CAPLUS

CN Imidazo[1,2-a]pyrazine, 2,3-dimethyl-8-(phenylmethoxy)- (CA INDEX NAME)




IT 85333-46-6

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(preparation and structure-activity relations of substituted imidazopyridines and related analogs as antiulcer agents)

RN 85333-46-6 CAPLUS

CN Imidazo[1,2-a]pyrazin-3-amine, 2-methyl-8-(phenylmethoxy)- (CA INDEX NAME)



REFERENCE COUNT: 23 THERE ARE 23 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 11 OF 29 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1997:44647 CAPLUS

DOCUMENT NUMBER: 126:74840

TITLE: Preparation of imidazo[1,2-a]pyridines as bone resorption inhibitors

INVENTOR(S): Kawai, Yoshio; Satoh, Shigeki; Yamazaki, Hitoshi; Kayakiri, Natsuko; Yoshihara, Kousei; Oku, Teruo

PATENT ASSIGNEE(S): Fujisawa Pharmaceutical Co., Ltd., Japan

SOURCE: PCT Int. Appl., 178 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	---	----	-----	-----
WO 9634866	A1	19961107	WO 1996-JP1103	19960423 <--
W: AU, CA, CN, JP, KR, MX, US				
RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
AU 9653483	A	19961121	AU 1996-53483	19960423 <--
JP 11505524	T	19990521	JP 1996-533169	19960423 <--
PRIORITY APPLN. INFO.:			GB 1995-8826	A 19950501 <--
			GB 1995-12972	A 19950626 <--
			GB 1995-16647	A 19950814 <--
			WO 1996-JP1103	W 19960423 <--


OTHER SOURCE(S): MARPAT 126:74840

IT 185131-42-4P 185131-81-1P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of imidazo[1,2-a]pyridines as bone resorption inhibitors)


RN 185131-42-4 CAPLUS

CN Benzamide, 2,6-dichloro-N-(2-methylimidazo[1,2-a]pyrazin-8-yl)- (CA INDEX NAME)



RN 185131-81-1 CAPLUS

CN Benzamide, N-(3-bromo-2-methylimidazo[1,2-a]pyrazin-8-yl)-2,6-dichloro-
(CA INDEX NAME)



L5 ANSWER 12 OF 29 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1996:86801 CAPLUS

DOCUMENT NUMBER: 124:146154

TITLE: Preparation of imidazopyridine derivatives as
bradykinin antagonists

INVENTOR(S): Oku, Teruo; Kayakiri, Hiroshi; Sato, Shigeki; Abe,
Yoshito; Sawada, Yuki; Tanaka, Hirokazu

PATENT ASSIGNEE(S): Fujisawa Pharmaceutical Co, Japan

SOURCE: Jpn. Kokai Tokkyo Koho, 23 pp.

CODEN: JKXXAF

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 07242666	A	19950919	JP 1994-37276	19940308 <--
PRIORITY APPLN. INFO.:			JP 1994-37276	19940308 <--
OTHER SOURCE(S):	MARPAT 124:146154			
IT 173159-26-7P				

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(preparation of imidazopyridine derivs. as bradykinin antagonists)

RN 173159-26-7 CAPLUS

CN Acetamide, N-[3-[[3-bromo-2-methylimidazo[1,2-a]pyrazin-8-yl]oxy]methyl]-2,4-dichlorophenyl]-N-methyl- (CA INDEX NAME)




L5 ANSWER 13 OF 29 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1991:74705 CAPLUS
 DOCUMENT NUMBER: 114:74705
 TITLE: Antiulcer agents. 5. Inhibition of gastric H⁺/K⁺-ATPase by substituted imidazo[1,2-a]pyridines and related analogs and its implication in modeling the high affinity potassium ion binding site of the gastric proton pump enzyme
 AUTHOR(S): Kaminski, James J.; Wallmark, Bjorn; Briving, Carin; Andersson, Britt Marie
 CORPORATE SOURCE: Dep. Chem. Res., Schering-Plough Corp., Bloomfield, NJ, 07003, USA
 SOURCE: Journal of Medicinal Chemistry (1991), 34(2), 533-41
 CODEN: JMCMAR; ISSN: 0022-2623
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 IT 85333-46-6
 RL: BIOL (Biological study)
 (stomach ATPase and acid secretion inhibition by, mol. modeling in relation to)
 RN 85333-46-6 CAPLUS
 CN Imidazo[1,2-a]pyrazin-3-amine, 2-methyl-8-(phenylmethoxy)- (CA INDEX NAME)




L5 ANSWER 14 OF 29 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1990:604675 CAPLUS
 DOCUMENT NUMBER: 113:204675
 TITLE: Structure and function of rat parietal cells during

treatment with omeprazole, SCH 28080, SCH 32651, or ranitidine
 AUTHOR(S): Helander, H. F.; Mattsson, H.; Elm, G.; Ottosson, S.
 CORPORATE SOURCE: Dep. Biol., AB Haessle, Molndal, Swed.
 SOURCE: Scandinavian Journal of Gastroenterology (1990), 25(8), 799-809
 CODEN: SJGRA4; ISSN: 0036-5521
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 IT 85333-47-7, SCH 32651
 RL: BIOL (Biological study)
 (stomach parietal cell structure and function response to, as proton pump inhibitor)
 RN 85333-47-7 CAPLUS
 CN Imidazo[1,2-a]pyrazin-3-amine, 2-methyl-8-(phenylmethoxy)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

L5 ANSWER 15 OF 29 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1990:526044 CAPLUS
 DOCUMENT NUMBER: 113:126044
 TITLE: Computer-automated structure evaluation of gastric antiulcer compounds: study of cytoprotective and antisecretory imidazo[1,2-a]pyridines and -pyrazines
 Klopman, Gilles; Srivastava, Sanjay
 AUTHOR(S): Dep. Chem., Case West. Reserve Univ., Cleveland, OH, 44106, USA
 CORPORATE SOURCE: Molecular Pharmacology (1990), 37(6), 958-65
 SOURCE: CODEN: MOPMA3; ISSN: 0026-895X
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 IT 85333-46-6 85333-49-9
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (antiulcer activity of, computer-automated structure evaluation of)
 RN 85333-46-6 CAPLUS
 CN Imidazo[1,2-a]pyrazin-3-amine, 2-methyl-8-(phenylmethoxy)- (CA INDEX NAME)



RN 85333-49-9 CAPLUS

CN Imidazo[1,2-a]pyrazin-3-amine, N-ethyl-2-methyl-8-(phenylmethoxy)- (CA INDEX NAME)



L5 ANSWER 16 OF 29 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1989:477237 CAPLUS

DOCUMENT NUMBER: 111:77237

TITLE: Antiulcer agents. 4. Conformational considerations and the antiulcer activity of substituted imidazo[1,2-a]pyridines and related analogs
 AUTHOR(S): Kaminski, James J.; Puchalski, Chester; Solomon, Daniel M.; Rizvi, Razia K.; Conn, David J.; Elliott, Arthur J.; Lovey, Raymond G.; Guzik, Henry; Chiu, P. J. S.; et al.

CORPORATE SOURCE: Pharm. Res. Div., Schering Res., Bloomfield, NJ, 07003, USA

SOURCE: Journal of Medicinal Chemistry (1989), 32(8), 1686-700
 CODEN: JMCMAR; ISSN: 0022-2623

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 111:77237


IT 85333-46-6

RL: PRP (Properties)

(gastric antisecretory and cytoprotective activity of)

RN 85333-46-6 CAPLUS

CN Imidazo[1,2-a]pyrazin-3-amine, 2-methyl-8-(phenylmethoxy)- (CA INDEX NAME)



L5 ANSWER 17 OF 29 CAPLUS COPYRIGHT 2008 ACS on STN


ACCESSION NUMBER: 1988:631072 CAPLUS

DOCUMENT NUMBER: 109:231072
 ORIGINAL REFERENCE NO.: 109:38225a,38228a
 TITLE: 8-Alkylaminoimidazo[1,2-a]pyrazine derivatives, their preparation, and their application in therapy
 INVENTOR(S): Sablayrolles, Claire; Bonnet, Pierre Antoine; Cros, Gerard; Chapat, Jean Pierre; Boucard, Maurice
 PATENT ASSIGNEE(S): Byk-Gulden Lomberg Chemische Fabrik G.m.b.H., Fed. Rep. Ger.
 SOURCE: PCT Int. Appl., 41 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 8804298	A1	19880616	WO 1987-EP756	19871204 <--
W: JP, US				
RW: AT, BE, CH, DE, FR, GB, IT, LU, NL, SE				
FR 2607813	A1	19880610	FR 1986-17164	19861205 <--
FR 2607813	B1	19890331		
EP 348392	A1	19900103	EP 1988-900690	19871204 <--
R: AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE				
JP 02501575	T	19900531	JP 1988-500907	19871204 <--
US 5028605	A	19910702	US 1989-364428	19890602 <--
PRIORITY APPLN. INFO.:			FR 1986-17164	A 19861205 <--
			WO 1987-EP756	W 19871204 <--

OTHER SOURCE(S): CASREACT 109:231072; MARPAT 109:231072


IT 117718-79-3P 117718-81-7P 117736-93-3P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of, as drug)
 RN 117718-79-3 CAPLUS
 CN Imidazo[1,2-a]pyrazin-8-amine, 3,6-dibromo-N-(2-furanylmethyl)- (CA INDEX NAME)



RN 117718-81-7 CAPLUS
 CN Imidazo[1,2-a]pyrazin-8-amine, N-(2-furanylmethyl)- (CA INDEX NAME)




RN 117736-93-3 CAPLUS
CN Imidazo[1,2-a]pyrazin-8-amine, 6-bromo-N-(2-furanylmethyl)- (CA INDEX NAME)



L5 ANSWER 18 OF 29 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1988:21791 CAPLUS
DOCUMENT NUMBER: 108:21791
ORIGINAL REFERENCE NO.: 108:3695a,3698a
TITLE: Antiulcer agents. 2. Gastric antisecretory, cytoprotective, and metabolic properties of substituted imidazo[1,2-a]pyridines and analogs
AUTHOR(S): Kaminski, James J.; Hilbert, James M.; Pramanik, B. N.; Solomon, Daniel M.; Conn, David J.; Rizvi, Razia K.; Elliott, Arthur J.; Guzik, Henry; Lovey, Raymond G.; et al.
CORPORATE SOURCE: Pharm. Res. Div., Schering-Plough Corp., Bloomfield, NJ, 07003, USA
SOURCE: Journal of Medicinal Chemistry (1987), 30(11), 2031-46
CODEN: JMCMAR; ISSN: 0022-2623
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 108:21791
IT 110223-35-3P
RL: PRP (Properties); SPN (Synthetic preparation); PREP (Preparation) (preparation and crystal structure of)
RN 110223-35-3 CAPLUS
CN Imidazo[1,2-a]pyrazin-3-amine, 2-methyl-8-(phenylmethoxy)-, (2Z)-2-butenedioate (2:1) (CA INDEX NAME)


CRN 85333-46-6
CMF C14 H14 N4 O




CM 2

CRN 110-16-7
CMF C4 H4 O4


Double bond geometry as shown.



IT 85333-46-6P 85333-49-9P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation and gastric antisecretory and cytoprotective activities of)
RN 85333-46-6 CAPLUS
CN Imidazo[1,2-a]pyrazin-3-amine, 2-methyl-8-(phenylmethoxy)- (CA INDEX
NAME)




RN 85333-49-9 CAPLUS
CN Imidazo[1,2-a]pyrazin-3-amine, N-ethyl-2-methyl-8-(phenylmethoxy)- (CA
INDEX NAME)




IT 85333-44-4P 110223-28-4P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 85333-44-4 CAPLUS

CN Imidazo[1,2-a]pyrazine, 2-methyl-8-(phenylmethoxy)- (CA INDEX NAME)



RN 110223-28-4 CAPLUS

CN Imidazo[1,2-a]pyrazin-3-amine, N-ethyl-2-methyl-8-(phenylmethoxy)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

L5 ANSWER 19 OF 29 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1987:598179 CAPLUS

DOCUMENT NUMBER: 107:198179

ORIGINAL REFERENCE NO.: 107:31795a,31798a

TITLE: Antiulcer agents. 3. Structure-activity-toxicity relationships of substituted imidazo[1,2-a]pyridines and a related imidazo[1,2-a]pyrazine

AUTHOR(S): Kaminski, James J.; Perkins, D. G.; Frantz, J. D.; Solomon, Daniel M.; Elliott, Arthur J.; Chiu, P. J. S.; Long, James F.

CORPORATE SOURCE: Pharm. Res. Div., Schering-Plough Corp., Bloomfield, NJ, 07003, USA

SOURCE: Journal of Medicinal Chemistry (1987), 30(11), 2047-51

CODEN: JMCMAR; ISSN: 0022-2623

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 107:198179


IT 85333-46-6

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)


(antiulcer activity of)

RN 85333-46-6 CAPLUS

CN Imidazo[1,2-a]pyrazin-3-amine, 2-methyl-8-(phenylmethoxy)- (CA INDEX NAME)



L5 ANSWER 20 OF 29 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1987:568562 CAPLUS
 DOCUMENT NUMBER: 107:168562
 ORIGINAL REFERENCE NO.: 107:26899a,26902a
 TITLE: SCH 28080 is a more selective inhibitor than SCH 32651
 at the potassium site of gastric potassium/proton
 ATPase
 AUTHOR(S): Beil, Winfried; Starr, Ute; Sewing, Karl F.
 CORPORATE SOURCE: Abt. Allg. Pharmakol., Med. Hochsch. Hannover,
 Hannover, D-3000, Fed. Rep. Ger.
 SOURCE: European Journal of Pharmacology (1987),
 139(3), 349-52
 CODEN: EJPHAZ; ISSN: 0014-2999
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 IT 85333-47-7, SCH 32651
 RL: BIOL (Biological study)
 (hydrogen/potassium ATPase of stomach inhibition by, antiseecretory
 activity in relation to)
 RN 85333-47-7 CAPLUS
 CN Imidazo[1,2-a]pyrazin-3-amine, 2-methyl-8-(phenylmethoxy)-,
 monohydrochloride (9CI) (CA INDEX NAME)




● HC1

L5 ANSWER 21 OF 29 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1987:138443 CAPLUS
 DOCUMENT NUMBER: 106:138443
 ORIGINAL REFERENCE NO.: 106:22593a,22596a
 TITLE: Imidazopyridines and -pyrazines as antiulcer agents
 Ueda, Ikuo; Shiokawa, Youichi; Take, Kazuhiko; Itani,
 Hiromichi
 INVENTOR(S): Fujisawa Pharmaceutical Co., Ltd., Japan
 PATENT ASSIGNEE(S):
 SOURCE: Eur. Pat. Appl., 72 pp.
 CODEN: EPXXDW
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2


PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 204285	A1	19861210	EP 1986-107418	19860602 <--
EP 204285	B1	19920115		
R: AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE				
ZA 8603805	A	19870429	ZA 1986-3805	19860521 <--
US 4725601	A	19880216	US 1986-865331	19860521 <--
FI 8602210	A	19861205	FI 1986-2210	19860526 <--
DK 8602503	A	19861205	DK 1986-2503	19860528 <--
CA 1257264	A1	19890711	CA 1986-510496	19860530 <--
JP 62016483	A	19870124	JP 1986-128941	19860602 <--
AT 71625	T	19920215	AT 1986-107418	19860602 <--
NO 8602208	A	19861205	NO 1986-2208	19860603 <--
HU 40798	A2	19870227	HU 1986-2332	19860603 <--
CN 86104313	A	19870304	CN 1986-104313	19860603 <--
ES 555653	A1	19871201	ES 1986-555653	19860603 <--
AU 8658345	A	19861211	AU 1986-58345	19860604 <--
AU 593802	B2	19900222		
US 4782055	A	19881101	US 1986-942379	19861216 <--
PRIORITY APPLN. INFO.:				
			GB 1985-14080	A 19850604 <--
			GB 1985-30878	A 19851216 <--
			US 1986-865331	A2 19860521 <--
			EP 1986-107418	A 19860602 <--
			GB 1986-27736	A 19861120 <--
OTHER SOURCE(S): CASREACT 106:138443; MARPAT 106:138443				
IT 107248-22-6P 107248-23-7P				
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)				
(preparation of, as antiulcer agent)				
RN 107248-22-6 CAPLUS				
CN Imidazo[1,2-a]pyrazin-8-amine, 2-methyl-N-[(2-methylphenyl)methyl]-3-(2-propynyl)-, monohydrochloride (9CI) (CA INDEX NAME)				




● HCl

RN 107248-23-7 CAPLUS
 CN Imidazo[1,2-a]pyrazin-8-amine, 2-methyl-N-[(2-methylphenyl)methyl]-3-(2-propynyl)- (9CI) (CA INDEX NAME)



L5 ANSWER 22 OF 29 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1987:131501 CAPLUS
 DOCUMENT NUMBER: 106:131501
 ORIGINAL REFERENCE NO.: 106:21295a,21298a
 TITLE: Studies on the mechanism of action of the gastric
 microsomal hydrogen ion-potassium-activated ATPase
 inhibitors SCH 32651 and SCH 28080
 AUTHOR(S): Scott, Cynthia K.; Sundell, Erin; Castrovilly,
 Lorraine
 CORPORATE SOURCE: Res. Lab., Ortho Pharm. Corp., Raritan, NJ, 08869, USA
 SOURCE: Biochemical Pharmacology (1987), 36(1),
 97-104
 CODEN: BCPCA6; ISSN: 0006-2952
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 IT 85333-47-7, SCH 32651
 RL: BIOL (Biological study)
 (ATPase inhibition by, in stomach, secretion inhibition in relation to)
 RN 85333-47-7 CAPLUS
 CN Imidazo[1,2-a]pyrazin-3-amine, 2-methyl-8-(phenylmethoxy)-,
 monohydrochloride (9CI) (CA INDEX NAME)




● HCl


L5 ANSWER 23 OF 29 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1986:626651 CAPLUS
 DOCUMENT NUMBER: 105:226651
 ORIGINAL REFERENCE NO.: 105:36607a,36610a
 TITLE: 2-Methyl-3-amino-8-benzyloxyimidazo[1,2-a]pyrazine
 INVENTOR(S): Gallardo Carrera, Antonio
 PATENT ASSIGNEE(S): Fordonal S. A., Spain
 SOURCE: Span., 7 pp.

DOCUMENT TYPE: CODEN: SPXXAD
 LANGUAGE: Patent
 FAMILY ACC. NUM. COUNT: Spanish
 PATENT INFORMATION: 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
ES 537947	A1	19851101	ES 1984-537947	19841126 <--
PRIORITY APPLN. INFO.:			ES 1984-537947	19841126 <--
IT 105545-75-3				
RL: RCT (Reactant); RACT (Reactant or reagent) (oxidation of)				
RN 105545-75-3 CAPLUS				
CN Imidazo[1,2-a]pyrazine-3-carboxamide, 2-methyl-8-(phenylmethoxy)- (CA INDEX NAME)				




IT 85333-46-6P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of, as antiulcer drug)
 RN 85333-46-6 CAPLUS
 CN Imidazo[1,2-a]pyrazin-3-amine, 2-methyl-8-(phenylmethoxy)- (CA INDEX NAME)



L5 ANSWER 24 OF 29 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1986:14815 CAPLUS
 DOCUMENT NUMBER: 104:14815
 ORIGINAL REFERENCE NO.: 104:2417a,2420a
 TITLE: Inhibition of hydrogen(+), potassium(+)-ATPase by SCH 28080 and SCH 32651
 AUTHOR(S): Scott, Cynthia K.; Sundell, Erin
 CORPORATE SOURCE: Res. Lab., Ortho Pharm. Corp., Raritan, NJ, 08869, USA
 SOURCE: European Journal of Pharmacology (1985), 112(2), 268-70
 CODEN: EJPHAZ; ISSN: 0014-2999
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 IT 85333-47-7
 RL: BIOL (Biological study)
 (ATPase of stomach mucosa inhibition by, antisecretory mechanism in


relation to)
 RN 85333-47-7 CAPLUS
 CN Imidazo[1,2-a]pyrazin-3-amine, 2-methyl-8-(phenylmethoxy)-,
 monohydrochloride (9CI) (CA INDEX NAME)



● HCl

L5 ANSWER 25 OF 29 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1985:113532 CAPLUS
 DOCUMENT NUMBER: 102:113532
 ORIGINAL REFERENCE NO.: 102:17843a,17846a
 TITLE: 8-(2-Imidazolylmethoxy(thio, or amino))-imidazo[1,2-a]pyrazines and derivatives for treating hypertension
 INVENTOR(S): Saari, Walfred S.
 PATENT ASSIGNEE(S): Merck and Co., Inc. , USA
 SOURCE: U.S., 4 pp.
 CODEN: USXXAM
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 4483858	A	19841120	US 1982-436753	19821025 <--
PRIORITY APPLN. INFO.:			US 1982-436753	19821025 <--
OTHER SOURCE(S): CASREACT 102:113532; MARPAT 102:113532				
IT 95185-86-7P 95185-91-4P 95185-92-5P				
95185-93-6P 95186-08-6P 95186-09-7P				
RL: SPN (Synthetic preparation); PREP (Preparation)				
(preparation of)				
RN 95185-86-7 CAPLUS				
CN Imidazo[1,2-a]pyrazine, 8-[(4,5-dihydro-1H-imidazol-2-yl)methoxy]-, dihydrochloride (9CI) (CA INDEX NAME)				



● 2 HCl


RN 95185-91-4 CAPLUS

CN Imidazo[1,2-a]pyrazine, 8-[[(4,5-dihydro-1H-imidazol-2-yl)methyl]thio]-
(CA INDEX NAME)




RN 95185-92-5 CAPLUS

CN Imidazo[1,2-a]pyrazine, 8-[[(1-methyl-1H-imidazol-2-yl)methyl]thio]- (CA
INDEX NAME)




RN 95185-93-6 CAPLUS

CN Imidazo[1,2-a]pyrazine, 8-[(4,5-dihydro-1H-imidazol-2-yl)methoxy]- (CA
INDEX NAME)



RN 95186-08-6 CAPLUS

CN Imidazo[1,2-a]pyrazine, 8-[[[(4,5-dihydro-1H-imidazol-2-yl)methyl]thio]-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl


RN 95186-09-7 CAPLUS

CN Imidazo[1,2-a]pyrazine, 8-[[[(1-methyl-1H-imidazol-2-yl)methyl]thio]-, (2Z)-2-butenedioate (1:1) (CA INDEX NAME)

CM 1

CRN 95185-92-5


CMF C11 H11 N5 S




CM 2

CRN 110-16-7
CMF C4 H4 O4

Double bond geometry as shown.




L5 ANSWER 26 OF 29 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1984:583783 CAPLUS
DOCUMENT NUMBER: 101:183783
ORIGINAL REFERENCE NO.: 101:27653a,27656a
TITLE: Gastric cytoprotective properties of SCH 32651, a novel antiulcer agent
AUTHOR(S): Chiu, P. J. S.; Barnett, A.; Gerhart, C.; Policelli, M.; Kaminski, J.
CORPORATE SOURCE: Dep. Pharmacol., Schering-Plough Corp., Bloomfield, NJ, USA
SOURCE: Archives Internationales de Pharmacodynamie et de Therapie (1984), 270(1), 128-40
CODEN: AIPTAK; ISSN: 0003-9780
DOCUMENT TYPE: Journal
LANGUAGE: English
IT 85333-47-7
RL: BIOL (Biological study)
(antiulcer drug, cytoprotective properties of)
RN 85333-47-7 CAPLUS
CN Imidazo[1,2-a]pyrazin-3-amine, 2-methyl-8-(phenylmethoxy)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

L5 ANSWER 27 OF 29 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1984:583285 CAPLUS
DOCUMENT NUMBER: 101:183285
ORIGINAL REFERENCE NO.: 101:27553a,27556a
TITLE: Effects of SCH 32651 on resting and stimulated acid secretion in guinea-pig isolated fundic mucosa
AUTHOR(S): Barnett, Allen; Chiu, Peter J. S.; Tetzloff, Glen
CORPORATE SOURCE: Dep. Pharmacol., Schering-Plough Corp., Bloomfield, NJ, USA
SOURCE: British Journal of Pharmacology (1984), 83(1), 75-82


CODEN: BJPCBM; ISSN: 0007-1188
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 IT 85333-47-7
 RL: BIOL (Biological study)
 (stomach mucosa acid secretion response to, mechanism of)
 RN 85333-47-7 CAPLUS
 CN Imidazo[1,2-a]pyrazin-3-amine, 2-methyl-8-(phenylmethoxy)-,
 monohydrochloride (9CI) (CA INDEX NAME)



● HCl

L5 ANSWER 28 OF 29 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1984:483791 CAPLUS
 DOCUMENT NUMBER: 101:83791
 ORIGINAL REFERENCE NO.: 101:12745a,12748a
 TITLE: Gastric antiseecretory properties of SCH 32651
 AUTHOR(S): Chiu, P. J. S.; Barnett, A.; Tetzloff, G.; Kaminski,
 J.
 CORPORATE SOURCE: Dep. Pharmacol., Schering-Plough Corp., Bloomfield,
 NJ, USA
 SOURCE: Archives Internationales de Pharmacodynamie et de
 Therapie (1984), 270(1), 116-27
 CODEN: AIPTAK; ISSN: 0003-9780
 DOCUMENT TYPE: Journal
 LANGUAGE: English

IT 85333-47-7
 RL: BIOL (Biological study)
 (gastric antiseecretory properties of)
 RN 85333-47-7 CAPLUS
 CN Imidazo[1,2-a]pyrazin-3-amine, 2-methyl-8-(phenylmethoxy)-,
 monohydrochloride (9CI) (CA INDEX NAME)




● HCl

L5 ANSWER 29 OF 29 CAPLUS COPYRIGHT 2008 ACS on STN


ACCESSION NUMBER: 1983:438461 CAPLUS
 DOCUMENT NUMBER: 99:38461
 ORIGINAL REFERENCE NO.: 99:6045a,6048a
 TITLE: Imidazo[1,2-a]pyridines and pyrazines and
 pharmaceutical compositions containing them
 INVENTOR(S): Bristol, James Arthur; Puchalski, Chester; Lovey,
 Raymond George
 PATENT ASSIGNEE(S): Schering Corp., USA
 SOURCE: Eur. Pat. Appl., '77 pp.
 CODEN: EPXXDW
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 3
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 68378	A1	19830105	EP 1982-105411	19820621 <--
EP 68378	B1	19860305		
R: AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE				
US 4507294	A	19850326	US 1982-356052	19820308 <--
AT 18402	T	19860315	AT 1982-105411	19820621 <--
DK 8202844	A	19821227	DK 1982-2844	19820624 <--
FI 8202266	A	19821227	FI 1982-2266	19820624 <--
FI 73433	B	19870630		
FI 73433	C	19871009		
NO 8202128	A	19821227	NO 1982-2128	19820624 <--
NO 159724	B	19881024		
NO 159724	C	19890201		
AU 8285178	A	19830106	AU 1982-85178	19820624 <--
AU 556062	B2	19861023		
ZA 8204516	A	19840229	ZA 1982-4516	19820624 <--
JP 58013584	A	19830126	JP 1982-109694	19820625 <--
JP 04004318	B	19920127		
HU 28470	A2	19831228	HU 1982-2071	19820625 <--
HU 189595	B	19860728		
IL 66141	A	19870227	IL 1982-66141	19820625 <--
CA 1248957	A1	19890117	CA 1982-406007	19820625 <--
US 4450164	A	19840522	US 1982-450885	19821220 <--
CA 1202630	A1	19860401	CA 1983-423133	19830308 <--
PRIORITY APPLN. INFO.:			US 1981-277576	A 19810626 <--
			US 1982-356052	A 19820308 <--
			US 1980-114473	A2 19800123 <--
			ZA 1981-219	A 19810113 <--
			EP 1982-105411	A 19820621 <--


OTHER SOURCE(S): CASREACT 99:38461; MARPAT 99:38461
 IT 85333-44-4P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (preparation and nitrosation of)
 RN 85333-44-4 CAPLUS
 CN Imidazo[1,2-a]pyrazine, 2-methyl-8-(phenylmethoxy)- (CA INDEX NAME)




IT 85333-45-5P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (preparation and reduction of)
 RN 85333-45-5 CAPLUS
 CN Imidazo[1,2-a]pyrazine, 2-methyl-3-nitroso-8-(phenylmethoxy)- (CA INDEX
 NAME)




IT 85333-40-0P 85333-46-6P 85333-47-7P
 85333-48-8P 85333-49-9P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)
 RN 85333-40-0 CAPLUS
 CN Imidazo[1,2-a]pyrazine, 2,3-dimethyl-8-(phenylmethoxy)- (CA INDEX NAME)



RN 85333-46-6 CAPLUS
 CN Imidazo[1,2-a]pyrazin-3-amine, 2-methyl-8-(phenylmethoxy)- (CA INDEX
 NAME)




RN 85333-47-7 CAPLUS
 CN Imidazo[1,2-a]pyrazin-3-amine, 2-methyl-8-(phenylmethoxy)-,
 monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 85333-48-8 CAPLUS
 CN Imidazo[1,2-a]pyrazine-3-acetonitrile, 2-methyl-8-(phenylmethoxy)- (CA
 INDEX NAME)



RN 85333-49-9 CAPLUS
 CN Imidazo[1,2-a]pyrazin-3-amine, N-ethyl-2-methyl-8-(phenylmethoxy)- (CA
 INDEX NAME)



=>

=>

=>

=>

=>

=>

=> log hold
 COST IN U.S. DOLLARS
 FULL ESTIMATED COST

SINCE FILE	TOTAL
ENTRY	SESSION
129.99	309.02

SESSION WILL BE HELD FOR 120 MINUTES
 STN INTERNATIONAL SESSION SUSPENDED AT 13:48:24 ON 09 APR 2008